Taşdemir, 179 patient famotidine late treatment study: 45% lower mortality [p=0.29], 37% lower ICU admission [p=0.36], 18% shorter hospitalization [p=0.003], and 20% faster recovery [p=0.04] https://c19p.org/tasdemir
copied to clipboard
Famotidine in COVID-19 treatment
et al., Konuralp Tıp Dergisi, doi:10.18521/ktd.935888
Retrospective 179 hospitalized patients in Turkey, 85 treated with famotidine and 94 treated with pantoprazole, showing faster recovery with famotidine in unadjusted results.
|
risk of death, 44.7% lower, RR 0.55, p = 0.29, treatment 5 of 85 (5.9%), control 10 of 94 (10.6%), NNT 21.
|
|
risk of ICU admission, 36.8% lower, RR 0.63, p = 0.36, treatment 8 of 85 (9.4%), control 14 of 94 (14.9%), NNT 18.
|
|
hospitalization time, 18.1% lower, relative time 0.82, p = 0.003, treatment 85, control 94.
|
|
recovery time, 20.0% lower, relative time 0.80, p = 0.04, treatment 85, control 94, duration of fever.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in the after exclusion results of meta
analysis:
excessive unadjusted differences between groups.
Taşdemir et al., 12 Jul 2021, retrospective, Turkey, peer-reviewed, 7 authors, this trial compares with another treatment - results may be better when compared to placebo.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.